

RECEIVED
CENTRAL FAX CENTER
JAN 07 2009

Amendment to the Claims

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

1-35. (Cancelled)

36. (Currently amended) An isolated peptide derived from BFA5 as shown in Table X IV or XI V.

37. (Currently amended) A method for immunizing a host against the tumor antigen BFA5 comprising administering to the patient a peptide of claim 36, ~~either alone or in combination with another agent, where the individual components of the combination are administered simultaneously or separately from one another.~~

38-66. (Cancelled)

67. (New) An isolated peptide of claim 36, the peptide being selected from the group consisting of LMDMQTFKA (SEQ ID NO.:7), SQYSGQLKV (SEQ ID NO.:38), and ELCSVRLTL (SEQ ID NO.:70).

68. (New) A composition comprising an isolated peptide of claim 36 and a pharmaceutically acceptable carrier.

69. (New) A composition comprising an isolated peptide of claim 67 and a pharmaceutically acceptable carrier.

70. (New) The method of claim 37 wherein the peptide selected from the group consisting of LMDMQTFKA (SEQ ID NO.:7), SQYSGQLKV (SEQ ID NO.:38), and ELCSVRLTL (SEQ ID NO.:70).

71. (New) The method of claim 37 wherein the peptide is administered alone or in combination with another agent wherein the individual components of the combination are administered simultaneously or separately from one another.

72. (New) The method of claim 70 wherein the peptide is administered alone or in combination with another agent wherein the individual components of the combination are administered simultaneously or separately from one another.